Lineage Cell Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

by Business Wire • 2022/08/11 • 0 Comments

CARLSBAD, Calif.--(BUSINESS WIRE)---- $LCTX #LineageCellTherapeutics--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported financial and operating results for the second quarter of 2022. Lineage management will host a conference call and webcast today at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its second quarter 2022 financial and operating results and to provide a business update. “We a

← Online learning tool for retina leads to measurable performance improvement

Aura Biosciences Reports Second Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights →

Post navigation